CDK4 and neoplasm: At the same time, we stained cell cycle pathway-related molecules in tumor tissues, and the results showed that compared with the control groups, the staining of p21 and p27 was stronger, while the staining of CDK4 and CDK6 was weaker in the bortezomib-treated groups (Fig. S9A, B).